Aclaris Therapeutics (ACRS) Reports A-101 45% Topical Solution Meets Primary/Secondary Efficacy Endpoints in 2nd Ph.3 Clinical Trial for Treament of THWART-1
Go back to Aclaris Therapeutics (ACRS) Reports A-101 45% Topical Solution Meets Primary/Secondary Efficacy Endpoints in 2nd Ph.3 Clinical Trial for Treament of THWART-1| (NASDAQ: ACRS) | Delayed: 5.50 +0.10 (1.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $5.40 | 52 Week High | $33.88 | |||
| Open | $5.41 | 52 Week Low | $14.12 | |||
| Day High | $5.54 | P/E | N/A | |||
| Day Low | $5.36 | EPS | $0.00 | |||
| Volume | 4,687,999 | |||||
